About Us | Contact Us |        

Metastatic Colorectal Cancer: Improving Care Across the Disease Continuum

Hematology-Oncology
Curriculum:
Metastatic Colorectal Cancer: Improving Care Across the Disease Continuum
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
May 21, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncologists

Relevant Terms:

mCRC, colorectal cancer, metastatic

John L. Marshall, MD

John L. Marshall, MD
Chief, Division of Hematology and Oncology
Director of Development Therapeutics and GI Oncology
Professor of Medicine and Oncology

Lombardi Cancer Center
Georgetown University Hospital
Washington, DC

Dr. John L. Marshall received his training at Duke University, the University of Louisville, and Georgetown University. Dr. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and he has served as principal investigator for more than 100 clinical trials. While he has an interest in many areas of cancer research, his primary focus has been on the development of vaccines to treat cancer. Dr. Marshall has become an outspoken advocate for GI cancer patients and the importance of clinical research participation. Most recently, he has established the Otto J Ruesch Center for the Cure of GI Cancers, an organization solely focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy. 

Axel Grothey, MD

Axel Grothey, MD
Professor of Oncology
Mayo Clinic
Rochester, Minnesota

Axel Grothey, MD, is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School. He is a member of Mayo Clinic's Cancer Center.
 
Dr. Grothey received his medical degree at Ruhr-Universitat Bochum, Germany, and completed residencies at West-German Tumorcenter and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum. He also completed a research fellowship at MD Cancer Center at the University of Texas. He joined Mayo Clinic as a consultant in 2005.
 
Dr. Grothey's clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He currently chairs the NCI colon cancer task force and serves as vice-chair of the gastrointestinal cancer committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chair of the Academic and Community Cancer Research United (ACCRU) international research network.
 
He currently holds professional positions in the Association of German Internists, German Cancer Association, Working Group of Experimental Cancer Research in Germany, American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, MD Anderson Associates, American Society of Clinical Oncology, European Society for Medical Oncology, German Association for Internal Oncology, and the Minnesota Medical Association. He also has served in various leadership positions at Mayo Clinic Cancer Center.
 
Dr. Grothey serves in journal review and editorial activities for numerous medical journals and is editor for Clinical Colorectal Cancer, Emerging Cancer Therapeutics, OncologySTAT, and Therapeutic Advances in Medical Oncology. In educational activities, he has served as a teacher, and he is a five-time recipient of Teacher of the Year recognition at Mayo Clinic. Dr. Grothey has given numerous international, national and regional presentation as well as invited and visiting professor presentations. He has co-authored more than 250 articles, books, book chapters, editorials, abstracts, and letters.

Wells Messersmith, MD, FACP

Wells Messersmith, MD, FACP
Professor and Head, Division of Medical Oncology
Director, GI Medical Oncology Program
Co-Director, Developmental Therapeutics
University of Colorado Denver
Aurora, Colorado

Wells Messersmith, MD, FACP, joined the University of Colorado Denver faculty in August 2007 as the director of Gastrointestinal Medical Oncology and was appointed co-leader of Developmental Therapeutics Program in 2010 as well as Head of the Division of Medical Oncology in 2014. He trained in internal medicine at Massachusetts General Hospital/Harvard Medical School and did his Medical Oncology/Drug Development Fellowship at Johns Hopkins, where he was awarded an ASCO Young Investigator Award and Passano Clinician-Scientist Award. He was on the Hopkins faculty from 2004 to 2007 as assistant professor in the GI Oncology and Drug Development programs.
1. Identify key molecular pathways involved in the pathogenesis of mCRC to assist in making targeted treatment decisions 
2. Describe efficacy and safety data for new and emerging treatments for mCRC 
3. Implement evidence-based treatment strategies and optimize sequencing of treatment for mCRC across the disease continuum

PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • John L. Marshall, MD, has affiliations with Argen, Bayer, Celgene, Genentech (Consulting, Speaker, Research).
  • Axel Grothey, MD, has no affiliations with commercial interests relative to the content to disclose.
  • Wells Messersmith, MDhas affiliations with Bayer, Genentech/Roche, Pfizer (Research)
RMEI, LLC
  • Boris Rozenfeld, MD, has no affiliations with commercial interests relative to the content to disclose.
  • Amy Reeve has no affiliations with commercial interests relative to the content to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.0 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

STATEMENT OF SUPPORT
This activity is supported by an independent educational grant from Genentech.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above